19 April 2023 - NICE has published evidence based recommendations on eladocagene exuparvovec (Upstaza) for the treatment of patients 18 ...
12 April 2023 - Public comment period now open until 9 May 2023; Requests to make oral comment during public ...
11 April 2023 - RGX-202 is a potential one-time AAV therapeutic for the treatment of Duchenne and includes an optimised transgene ...
3 April 2023 - EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review ...
23 March 2023 - The first and currently only gene therapy for children with an ultra-rare genetic disorder has been recommended ...
20 March 2023 - A top FDA official said Monday that the agency needs to start using accelerated approval, a ...
9 March 2023 - Report will be subject of CTAF meeting in September 2023; draft scoping document open to public ...
9 March 2023 - A decade ago, I had pegged gene and cell therapies as the next frontier. As an ...
7 March 2023 - Genethon today announced that the EMA has granted PRIME (Priority Medicines) status to the gene therapy, ...
7 March 2023 - FDA extends PDUFA target action date to 30 June 2023. ...
6 March 2023 - The discussion will likely begin in earnest this month to expand reimbursement criteria for Spinraza (nusinersen ...
21 February 2023 - PDUFA date set for 8 October 2023. ...
20 February 2023 - Hemgenix underscores CSL's promise to deliver life-changing innovations that have the potential to help patients lead ...
16 February 2023 - A toddler with a rare inherited condition has become the first child to be treated by ...
14 February 2023 - More than 1,000 cell and gene therapy clinical trials registered. ...